Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market dynamics of rheumatic fever have changed significantly due to developments in diagnostic techniques, treatment methods, and the awareness about this inflammatory disease. Rheumatic fever is a serious consequence of untreated streptococcus infections of the throat that increasingly has been identified promptly. Diagnostic accuracy and speed in rheumatic fever which allow for timely management and prevention of complications have been improved by employing molecular biology and serology tests among other diagnostic tools.
Rf therapeutic landscape witnessed a shift towards patient-centered care. The recurrent nature of rheumatic fever could be avoided by prescribing antibiotics targeting the underlying streptococcal infection. In the same vein, nonsteroidal anti-inflammatory drugs (NSAIDs) as well as corticosteroids help reduce discomfort and inflammation characteristic of this condition. A multi-disciplinary approach seems to be emerging as a trend in treating RF that takes into account not only acute period but also long-term consequences such as rheumatic heart disease.
One significant market trend is towards prevention measures aimed at stopping streptococcal infections from advancing to rheumatic fever. Early detection and prompt treatment of Streptococcus pyogenes throats are being made possible through public health initiatives, campaigning, and increased knowledge among healthcare providers, even leading to a reduction in the incidence rate of RF. There are also proposals for vaccination against certain strains of streptococcus, all geared towards preventive approach in handling the root causes for this illness.
Global partnerships between groups have become more pronounced within the RF market. This involves governments’ efforts to share resources among other stakeholders like pharmaceuticals companies or non-governmental organizations for research purposes. Such interactives are aimed at addressing broader challenges surrounding RF thus enabling new therapies, diagnostics or preventative strategies.
Technological advancements especially those related to telemedicine and digital health are shaping how rheumatic fever is treated today. Telemedicine enables virtual consultations with doctors remotely thereby overcoming geographical boundaries while guaranteeing access to healthcare services. This has become even more significant amid the Covid-19 pandemic where telehealth solutions have been critical in ensuring continued care for rheumatic fever patients and other related conditions.
The growing importance of patient advocacy and support networks is another noticeable trend within the RF market. These groups play an active role in raising awareness, helping patients as well as their families and lobbying for policy changes that would improve accessibility to treatment. Such a collaborative effort seeks to empower those with RF condition, fight against stigma associated with it, and make communities better understand the ailment.
Regulatory considerations are important in the rheumatic fever market since they allow regulatory agencies to streamline regulatory approval processes for relevant therapies or interventions. This collaboration between regulators, medical professionals and stakeholders of industry is needed so that safe and effective therapies can be made available to people with Rf disease.
Rheumatic Fever Market Highlights:
Global Rheumatic Fever Market Overview
Rheumatic Fever Market Size was valued at USD 0.23 Billion in 2023. The Global Rheumatic Fever industry is projected to grow from USD 0.36 Billion in 2024 to USD 1.37 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.82% during the forecast period (2024 - 2032).
Rheumatic fever is an autoimmune inflammatory disease which can develop as a complication of inadequately treated strep throat. Strep throat is a condition caused by group a Streptococcus bacterium. Rheumatic fever is common in the age group of 5 to 15 years, but adults can also have the condition. In certain cases, rheumatic fever can cause long-term damage to the heart and heart valves.
The increasing occurrences of strep throat and growing prevalence of rheumatic heart disease are expected to be the major drivers for the growth of the market during the forecast period. Moreover, increasing government expenditure for the healthcare sector contributes to the market growth. According to the World Health Organization (WHO) report published in April 2018, approximately 30 million people are affected by rheumatic heart disease globally.
Despite the drivers, lack of awareness about the condition and limited healthcare facilities in emerging economies may hamper the growth of the market during the assessment period.
Oakrum Pharma, LLC and ANI Pharmaceuticals announced in February 2022 that the FDA approved a generic version of Cystadane1 (betaine anhydrous for oral solution) Powder in a 180-gm bottle, which was granted Competitive Generic Therapy (CGT) of 180 days of exclusivity.
Viatris Inc., the parent to Mylan Pharmaceuticals Inc., disclosed this information in February 2022 when it got the FDA’s approval on its Abbreviated New Drug Application (ANDA) for Cyclosporine Ophthalmic Emulsion 0.05%, which is the First generic version of Allergan’s Restasis® to be approved. There are no legal or regulatory barriers, and the company started operating right away.
In June 2023, New Zealand’s Associate Minister of Health for Pacific Peoples launched a further initiative aimed at reducing rheumatic fever. MP Barbara Edmonds said almost two-thirds of all rheumatic fever cases were among Pacific people. The Rheumatic Fever Roadmap 2023 - 2028 has been unveiled by Edmonds in Auckland this week to prevent, identify and treat rheumatic fever from around Aotearoa. Rheumatic fever is an autoimmune condition, according to Te Whatu Ora – New Zealand’s health authority. If untreated, strep throat can lead to rheumatic fever in at-risk children and young adults.
The American Society of Echocardiography (ASE) issued a new guideline document called “Recommendations on the Comprehensive Use of Echocardiography in Diagnosing and Therapeutic Intervention for ARF/RHD: A Report from the American Society of Echocardiography” in January, Journal of American Society Echocardiography Volume ___ issue ___. It had twenty-five ASE International Alliance Partners endorsements as an article that had been published by these societies. Among them, there is also a revised edition published with the title Recommendations for the Use of Echocardiography in Evaluating Rheumatic Heart Disease by the American Society of Echocardiography, out of all being updated to 2007 and 2009 guideline documents on valvular regurgitation or stenosis etiology, one of which was “Recommendations for the Use of Echocardiography in the Evaluation of Rheumatic Heart Disease: A Report from the American Society of Echocardiography”, under update. This new guideline is comprehensive and covers all uses of RHD.
Rheumatic Fever Market Segment Insights
The global rheumatic fever market has been segmented into diagnosis, treatment, distribution channel, and end-user.
Rheumatic Fever Diagnosis Insights
The market on the basis of diagnosis has been segmented into physical exam, blood test, electrocardiogram, and echocardiogram.
Rheumatic Fever Treatment Insights
The market, by treatment, has been segmented into pharmacotherapy and others. The pharmacotherapy segment is further segmented into antibiotics, anti-inflammatory medication, anticonvulsant medication, and others. Further, the anti-inflammatory medication segment has been segmented into aspirin, naproxen, and others.
Rheumatic Fever Distribution Channel Insights
The market, by distribution channel, has been segmented into retail pharmacies, hospital pharmacies, and others.
Rheumatic Fever End-User Insights
On the basis of end-user, the market has been segmented into hospitals and clinics, diagnostic centers, and others.
Rheumatic Fever Regional Insights
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rheumatic fever market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European rheumatic fever market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The rheumatic fever market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rheumatic fever market in the Middle East & Africa has been segmented into the Middle East and Africa.
Rheumatic Fever Market Top Key Players
Some of the key players in the global rheumatic fever market are:
- Bayer AG
- Abbott Laboratories
- Johnson & Johnson Services, Inc.
- F. Hoffman-La Roche Ltd.
- Novartis AG
- Pfizer, Inc.
- AstraZeneca
- Valeant Pharmaceuticals International, Inc.
- Eli Lilly and Company
Geographically, the Americas is anticipated to dominate the global rheumatic fever market owing to a well-developed healthcare sector, rising prevalence of cardiovascular diseases, and growing healthcare expenditure. According to the Centers for Disease Control and Prevention, approximately 610,000 people die of heart diseases in the US every year. Additionally, increasing awareness among the people regarding the disease and well-developed technology are likely to contribute to the growth of the market.
Europe is expected to hold the second largest position in the global rheumatic fever market. The market growth in this region is attributed to the growing prevalence of rheumatic heart disease, availability of funds for research, and increasing healthcare expenditure.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, growing occurrences of rheumatic fever, and increasing government funding for the healthcare sector.
On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to a well-developed healthcare sector and growing government initiatives for rheumatic heart disease. For instance, according to the RHD Global Status Report, 2015 to 2017, Egypt’s Rheumatic Heart Disease (RHD) programme trained 300 cardiologists and 1,500 primary healthcare physicians in rheumatic heart disease management in 2015. However, the market in the African region is expected to propel owing to the rising prevalence of rheumatic heart disease and increasing government initiatives for the prevention of rheumatic fever.
Rheumatic Fever Market Segment Analysis
Rheumatic Fever Diagnosis Outlook
- Physical Exam
- Blood Test
- Electrocardiogram
- Echocardiogram
Rheumatic Fever Treatment Outlook
- Pharmacotherapy
- Antibiotics
- Anti-inflammatory Medication
- Aspirin
- Naproxen
- Others
- Anticonvulsant Medication
- Others
- Others
Rheumatic Fever Distribution Channel Outlook
- Retail Pharmacies
- Hospital Pharmacies
- Others
Rheumatic Fever End-User Outlook
- Hospitals and Clinics
- Diagnostic Centers
- Others
Rheumatic Fever Regional Outlook
- Americas
-
- North America
- US
- Canada
- South America
- Europe
-
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
-
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
-
- Middle East
- Africa
Intended Audience
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
